Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

BACKGROUND: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti–epidermal growth factor receptor (EGFR) and anti–vascular...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Med Insights Oncol
Auteurs principaux: Dell’Aquila, Emanuela, Zeppola, Tea, Stellato, Marco, Pantano, Francesco, Scartozzi, Mario, Madaudo, Cristina, Pietrantonio, Filippo, Cremolini, Chiara, Aprile, Giuseppe, Vincenzi, Bruno, Moretto, Roberto, Puzzoni, Marco, Garattini, Silvio Ken, Lobefaro, Riccardo, Tonini, Giuseppe, Santini, Daniele
Format: Artigo
Langue:Inglês
Publié: SAGE Publications 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412900/
https://ncbi.nlm.nih.gov/pubmed/32821190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1179554920946693
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires